23 May , 2023
12:00 AM
02 Feb , 2023
12:00 AM
02 Feb , 2023
12:00 AM
Results
View Details02 Nov , 2022
12:00 AM
Results
View Details02 Nov , 2022
12:00 AM
03 Aug , 2022
12:00 AM
03 Aug , 2022
12:00 AM
Results
View DetailsCALLS | PUTS | |||||||||
Total OI | Chg in Ol | Chg % Ol | LTP | Chg % | Strike Price | Chg % | LTP | Chg % OI | Chg in Ol | Total OI |
No Record Found
sector: Pharmaceuticals
as on 3/28/2019 3:24:26 PM
₹ 3.3 -0.15 -4.3523 May , 2023
12:00 AM
02 Feb , 2023
12:00 AM
02 Feb , 2023
12:00 AM
Results
View Details02 Nov , 2022
12:00 AM
Results
View Details02 Nov , 2022
12:00 AM
03 Aug , 2022
12:00 AM
03 Aug , 2022
12:00 AM
Results
View DetailsPROMOTER - TOTAL0.00%
Indian: 0.00%
Foreign: 0%
NON-PROMOTER - TOTAL 100.00%
Institutions: 0.19%
Non-Institutions: 99.81%
CUSTODIES - 0.00%
Custodies: 0.00%
Invest wise with Expert advice
Get better recommendations Make better investments.
Get better recommendations Make better investments.
By continuing, I accept the Terms & Conditions and agree to receive communication on Whatsapp
Demat Account
Trading Account
According to Aditya Birla Capital Ltd., the preferential issuance would take place at a cost of Rs 165.1 per equity share and is pending approval from shareholders.
Resolution Type | Desc. of Resolution | Lias Recommendation |
---|
Particulars ( Rupees In Crores.) | -- | -- | -- | -- | -- |
---|---|---|---|---|---|
Gross Sales | -- | -- | -- | -- | |
Excise Duty | -- | -- | -- | -- | |
Net Sales | -- | -- | -- | -- | |
Other Operating Income | -- | -- | -- | -- | |
Other Income | -- | -- | -- | -- | |
Total Income | -- | -- | -- | -- | |
Total Expenditure ** | -- | -- | -- | -- | |
PBIDT | -- | -- | -- | -- | |
Interest | -- | -- | -- | -- | |
PBDT | -- | -- | -- | -- | |
Depreciation | -- | -- | -- | -- | |
Minority Interest Before NP | -- | -- | -- | -- | |
Tax | -- | -- | -- | -- | |
Deferred Tax | -- | -- | -- | -- | |
Reported Profit After Tax | -- | -- | -- | -- | |
Minority Interest After NP | -- | -- | -- | -- | |
Net Profit after Minority Interest | -- | -- | -- | -- | |
Extra-ordinary Items | -- | -- | -- | -- | |
Adjusted Profit After Extra-ordinary item | -- | -- | -- | -- | |
EPS (Unit Curr.) | -- | -- | -- | -- | |
Book Value (Unit Curr.) | -- | -- | -- | -- | |
Dividend (%) | -- | -- | -- | -- | |
Equity | -- | -- | -- | -- | |
Public Shareholding (Number) | -- | -- | -- | -- | |
Public Shareholding (%) | -- | -- | -- | -- | |
Pledged/Encumbered - No. of Shares | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Equity | -- | -- | -- | -- | |
Non Encumbered - No. of Shares | -- | -- | -- | -- | |
Non Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Non Encumbered - % in Total Equity | -- | -- | -- | -- | |
PBIDTM(%) | -- | -- | -- | -- | |
PBDTM(%) | -- | -- | -- | -- | |
PATM(%) | -- | -- | -- | -- |
No Record Found
Particulars ( Rupees In Crores.) | -- | -- | -- | -- | -- |
---|---|---|---|---|---|
Gross Sales | -- | -- | -- | -- | |
Excise Duty | -- | -- | -- | -- | |
Net Sales | -- | -- | -- | -- | |
Other Operating Income | -- | -- | -- | -- | |
Other Income | -- | -- | -- | -- | |
Total Income | -- | -- | -- | -- | |
Total Expenditure ** | -- | -- | -- | -- | |
PBIDT | -- | -- | -- | -- | |
Interest | -- | -- | -- | -- | |
PBDT | -- | -- | -- | -- | |
Depreciation | -- | -- | -- | -- | |
Minority Interest Before NP | -- | -- | -- | -- | |
Tax | -- | -- | -- | -- | |
Deferred Tax | -- | -- | -- | -- | |
Reported Profit After Tax | -- | -- | -- | -- | |
Minority Interest After NP | -- | -- | -- | -- | |
Net Profit after Minority Interest | -- | -- | -- | -- | |
Extra-ordinary Items | -- | -- | -- | -- | |
Adjusted Profit After Extra-ordinary item | -- | -- | -- | -- | |
EPS (Unit Curr.) | -- | -- | -- | -- | |
Book Value (Unit Curr.) | -- | -- | -- | -- | |
Dividend (%) | -- | -- | -- | -- | |
Equity | -- | -- | -- | -- | |
Public Shareholding (Number) | -- | -- | -- | -- | |
Public Shareholding (%) | -- | -- | -- | -- | |
Pledged/Encumbered - No. of Shares | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Equity | -- | -- | -- | -- | |
Non Encumbered - No. of Shares | -- | -- | -- | -- | |
Non Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Non Encumbered - % in Total Equity | -- | -- | -- | -- | |
PBIDTM(%) | -- | -- | -- | -- | |
PBDTM(%) | -- | -- | -- | -- | |
PATM(%) | -- | -- | -- | -- |
No Record Found
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd | 999.35 | 52.38 | 2,39,777.54 | -1,020.82 | 1.15 | 5,800.85 | 98.98 |
Divis Laboratories Ltd | 3,539.90 | 51.62 | 93,340.08 | 318.79 | 0.85 | 1,908.17 | 478.60 |
Cipla Ltd | 966.85 | 29.96 | 77,910.84 | 355.49 | 0.88 | 3,485.68 | 305.25 |
Dr Reddys Laboratories Ltd | 4,609.05 | 29.38 | 76,753.62 | 672.40 | 0.87 | 4,537.80 | 1,229.47 |
Torrent Pharmaceuticals Ltd | 1,774.00 | 57.17 | 60,134.99 | 219.00 | 1.24 | 1,882.00 | 190.76 |
Incorporated in 1989,Sharon Bio-Medicine Ltd is engaged in the pharmaceuticals/chemicals segment.The company had developed a number of products in active pharmaceutical ingredient (API), intermediates and formulations. During the fiscal year ended June 30, 2010, it had set up an active pharmaceutical ingredients plant in Taloja near Navi Mumbai.The company had installed capacity of 150,000 liters of reactors capacity of API and intermediates, and 2.5 billion tablets per shift per annum and one billion capsules per shift per annum. Its products include Trimetazidine Di Hydrochloride, Ketoconzole, Pentaprazole, Amlodipine Besylate, Atomoxetine Hcl, Carisoprodl, Closantel Base, Glimepiride, Ketoconazole, Nifedipibe, Racecadotril, Toldimfos, Telmisartan, Tamsulosin, Itraconazole, Mesalazine, Lansoprazole and Doxorubicin Inj.In January 2010,the Company started its toxicology laboratory and research and development unit at Taloja, Navi... Read More
Reports by Sharon Bio-Medicine Ltd
Reports by Sharon Bio-Medicine Ltd